Guidance for the 2025/26 financial year

Core Insights - ChemoMetec has approved its annual report for 2024/25 and provided guidance for the financial year 2025/26, indicating expected revenue and EBITDA growth [1][2] Financial Guidance - For the financial year 2025/26, ChemoMetec anticipates revenue between DKK 545 million and DKK 565 million, compared to DKK 495.6 million in 2024/25, representing an increase of approximately 10% to 14% [1] - The expected EBITDA for 2025/26 is projected to be between DKK 295 million and DKK 315 million, up from DKK 258 million in 2024/25, indicating a growth of around 14% to 22% [1] Company Overview - ChemoMetec specializes in developing, manufacturing, and marketing instruments for cell counting and various other measurements, serving the pharmaceutical, biotech, and agricultural industries globally [3][4] - The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen [4]